Inflammation  ||| S:0 E:13 ||| NNP
and  ||| S:13 E:17 ||| CC
repair  ||| S:17 E:24 ||| NN
mechanisms  ||| S:24 E:35 ||| NNS
Although  ||| S:35 E:44 ||| IN
both  ||| S:44 E:49 ||| DT
rheumatoid  ||| S:49 E:60 ||| JJ
arthritis  ||| S:60 E:70 ||| NN
( ||| S:70 E:71 ||| -LRB-
RA ||| S:71 E:73 ||| NNP
)  ||| S:73 E:75 ||| -RRB-
and  ||| S:75 E:79 ||| CC
ankyosing  ||| S:79 E:89 ||| JJ
spondylitis  ||| S:89 E:101 ||| NNS
( ||| S:101 E:102 ||| -LRB-
AS ||| S:102 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
belong  ||| S:106 E:113 ||| VBP
to  ||| S:113 E:116 ||| TO
the  ||| S:116 E:120 ||| DT
group  ||| S:120 E:126 ||| NN
of  ||| S:126 E:129 ||| IN
chronic  ||| S:129 E:137 ||| JJ
inflammatory  ||| S:137 E:150 ||| JJ
rheumatic  ||| S:150 E:160 ||| JJ
diseases ||| S:160 E:168 ||| NNS
,  ||| S:168 E:170 ||| ,
they  ||| S:170 E:175 ||| PRP
are  ||| S:175 E:179 ||| VBP
quite  ||| S:179 E:185 ||| RB
different  ||| S:185 E:195 ||| JJ
regarding  ||| S:195 E:205 ||| VBG
mechanisms  ||| S:205 E:216 ||| NNS
of  ||| S:216 E:219 ||| IN
inflammation  ||| S:219 E:232 ||| NN
and  ||| S:232 E:236 ||| CC
repair ||| S:236 E:242 ||| NN
.  ||| S:242 E:244 ||| .
While  ||| S:244 E:250 ||| IN
RA  ||| S:250 E:253 ||| NNP
is  ||| S:253 E:256 ||| VBZ
an  ||| S:256 E:259 ||| DT
erosive  ||| S:259 E:267 ||| JJ
destructive  ||| S:267 E:279 ||| JJ
disease  ||| S:279 E:287 ||| NN
with  ||| S:287 E:292 ||| IN
the  ||| S:292 E:296 ||| DT
synovium  ||| S:296 E:305 ||| NN
as  ||| S:305 E:308 ||| IN
the  ||| S:308 E:312 ||| DT
primary  ||| S:312 E:320 ||| JJ
site  ||| S:320 E:325 ||| NN
of  ||| S:325 E:328 ||| IN
inflammation ||| S:328 E:340 ||| NN
,  ||| S:340 E:342 ||| ,
the  ||| S:342 E:346 ||| DT
immune  ||| S:346 E:353 ||| JJ
response  ||| S:353 E:362 ||| NN
in  ||| S:362 E:365 ||| IN
AS  ||| S:365 E:368 ||| NNP
takes  ||| S:368 E:374 ||| VBZ
place  ||| S:374 E:380 ||| NN
primarily  ||| S:380 E:390 ||| RB
at  ||| S:390 E:393 ||| IN
the  ||| S:393 E:397 ||| DT
cartilage ||| S:397 E:406 ||| FW
/ ||| S:406 E:407 ||| FW
bone  ||| S:407 E:412 ||| FW
interface ||| S:412 E:421 ||| FW
,  ||| S:421 E:423 ||| ,
and  ||| S:423 E:427 ||| CC
the  ||| S:427 E:431 ||| DT
pathological  ||| S:431 E:444 ||| NN
but  ||| S:444 E:448 ||| CC
also  ||| S:448 E:453 ||| RB
the  ||| S:453 E:457 ||| DT
clinical  ||| S:457 E:466 ||| JJ
picture  ||| S:466 E:474 ||| NN
is  ||| S:474 E:477 ||| VBZ
determined  ||| S:477 E:488 ||| VBN
by  ||| S:488 E:491 ||| IN
an  ||| S:491 E:494 ||| DT
until  ||| S:494 E:500 ||| IN
not  ||| S:500 E:504 ||| RB
yet  ||| S:504 E:508 ||| RB
well  ||| S:508 E:513 ||| RB
defined  ||| S:513 E:521 ||| VBN
interaction  ||| S:521 E:533 ||| VBN
between  ||| S:533 E:541 ||| IN
inflammation  ||| S:541 E:554 ||| NN
and  ||| S:554 E:558 ||| CC
new  ||| S:558 E:562 ||| JJ
bone  ||| S:562 E:567 ||| NN
formation ||| S:567 E:576 ||| NN
.  ||| S:576 E:578 ||| .
Most  ||| S:578 E:583 ||| RBS
recently ||| S:583 E:591 ||| RB
,  ||| S:591 E:593 ||| ,
first  ||| S:593 E:599 ||| JJ
insights  ||| S:599 E:608 ||| NNS
into  ||| S:608 E:613 ||| IN
the  ||| S:613 E:617 ||| DT
molecular  ||| S:617 E:627 ||| JJ
mechanisms  ||| S:627 E:638 ||| NNS
between  ||| S:638 E:646 ||| IN
inflammation  ||| S:646 E:659 ||| NN
and  ||| S:659 E:663 ||| CC
bone  ||| S:663 E:668 ||| NN
destruction  ||| S:668 E:680 ||| NN
or  ||| S:680 E:683 ||| CC
new  ||| S:683 E:687 ||| JJ
bone  ||| S:687 E:692 ||| NN
formation  ||| S:692 E:702 ||| NN
could  ||| S:702 E:708 ||| MD
be  ||| S:708 E:711 ||| VB
obtained ||| S:711 E:719 ||| VBN
.  ||| S:719 E:721 ||| .
Key  ||| S:721 E:725 ||| JJ
molecules  ||| S:725 E:735 ||| NNS
involved  ||| S:735 E:744 ||| VBN
in  ||| S:744 E:747 ||| IN
bone  ||| S:747 E:752 ||| NN
homeostasis  ||| S:752 E:764 ||| NNS
seem  ||| S:764 E:769 ||| VBP
to  ||| S:769 E:772 ||| TO
differ  ||| S:772 E:779 ||| VB
between  ||| S:779 E:787 ||| IN
RA  ||| S:787 E:790 ||| NNP
and  ||| S:790 E:794 ||| CC
AS  ||| S:794 E:797 ||| NNP
patients ||| S:797 E:805 ||| NNS
.  ||| S:805 E:807 ||| .
While  ||| S:807 E:813 ||| IN
the  ||| S:813 E:817 ||| DT
molecules  ||| S:817 E:827 ||| JJ
sclerostin  ||| S:827 E:838 ||| NN
and  ||| S:838 E:842 ||| CC
dickkopf  ||| S:842 E:851 ||| CD
1 ||| S:851 E:852 ||| CD
,  ||| S:852 E:854 ||| ,
both  ||| S:854 E:859 ||| DT
inhibitors  ||| S:859 E:870 ||| NN
of  ||| S:870 E:873 ||| IN
osteoblasts ||| S:873 E:884 ||| NN
,  ||| S:884 E:886 ||| ,
are  ||| S:886 E:890 ||| VBP
elevated  ||| S:890 E:899 ||| VBN
in  ||| S:899 E:902 ||| IN
RA  ||| S:902 E:905 ||| NNP
they  ||| S:905 E:910 ||| PRP
are  ||| S:910 E:914 ||| VBP
found  ||| S:914 E:920 ||| VBN
to  ||| S:920 E:923 ||| TO
be  ||| S:923 E:926 ||| VB
rather  ||| S:926 E:933 ||| RB
low  ||| S:933 E:937 ||| JJ
in  ||| S:937 E:940 ||| IN
AS ||| S:940 E:942 ||| NNP
.  ||| S:942 E:944 ||| .
It  ||| S:944 E:947 ||| PRP
can  ||| S:947 E:951 ||| MD
be  ||| S:951 E:954 ||| VB
expected  ||| S:954 E:963 ||| VBN
that  ||| S:963 E:968 ||| IN
the  ||| S:968 E:972 ||| DT
rapidly  ||| S:972 E:980 ||| RB
expanding  ||| S:980 E:990 ||| VBG
new  ||| S:990 E:994 ||| JJ
field  ||| S:994 E:1000 ||| NN
of  ||| S:1000 E:1003 ||| IN
osteoimmunology  ||| S:1003 E:1019 ||| NNS
will  ||| S:1019 E:1024 ||| MD
help  ||| S:1024 E:1029 ||| VB
to  ||| S:1029 E:1032 ||| TO
clarify  ||| S:1032 E:1040 ||| VB
the  ||| S:1040 E:1044 ||| DT
pathogenesis  ||| S:1044 E:1057 ||| NN
of  ||| S:1057 E:1060 ||| IN
the  ||| S:1060 E:1064 ||| DT
these  ||| S:1064 E:1070 ||| DT
two  ||| S:1070 E:1074 ||| CD
diseases  ||| S:1074 E:1083 ||| NNS
with  ||| S:1083 E:1088 ||| IN
possible  ||| S:1088 E:1097 ||| JJ
implications  ||| S:1097 E:1110 ||| NNS
for  ||| S:1110 E:1114 ||| IN
new  ||| S:1114 E:1118 ||| JJ
treatment  ||| S:1118 E:1128 ||| NN
targets ||| S:1128 E:1135 ||| NNS
.  ||| S:1135 E:1137 ||| .
